Oxford Biodynamics launches collaboration to improve autism diagnosis techniques

Oxford Biodynamics entered into a collaboration with Casa Sollievo della Sofferenza on Monday to research the blood-based diagnosis of Autism Spectrum Disorder (ASD).

The two parties are aiming to develop a diagnostic biomarker assay for ASD, using Oxford Biodynamics’ EpiSwitch technology platform and blood samples from both autistic subjects and healthy controls provided by Casa Sollievo.

The Italian outfit is “a recognised research and biomedical institution of national importance,” according to a statement released by Oxford Biodynamics.

Alexandre Akoulitchev, chief scientific officer of Oxford BioDynamics, said: "We are highly appreciative of the great expertise and ASD insights from our Italian colleagues. We strongly believe our work will help to improve the understanding of epigenetic controls and mechanisms behind this disorder."

Diagnosis remains challenging due to broad ranging symptoms and differential progression and manifestation of the disorder.

"This agreement further demonstrates rising interest in our proprietary technology, EpiSwitch, which offers results of unique value and clinical utility in biomarker discovery and disease understanding for a broad spectrum of complex indications, from immune-oncology and autoimmune conditions, to neurodegeneration, psychiatric and neurodevelopmental conditions," said Akoulitchev.

ASD is thought to be caused by a complex interaction of genetic, epigenetic and environmental factors, and represents a group of neurodevelopmental disorders, characterised by problems with social interaction, and it is estimated that approximately 1 in every 100 people in the UK has ASD.

There is no cure but speech and language therapy, occupational therapy and educational support can be deployed to improve the lives of patients, with earlier diagnosis allowing for more timely intervention.

Oxford Biodynamics’ shares were down 1.80% at 206.00p at 0926 GMT